Close

Oxygen Biotherapeutics (OXBT) Oxycyte Phase IIb Traumatic Brain Injury Trial Halted

September 11, 2014 5:31 PM EDT Send to a Friend
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that the Company, with unanimous approval from the Board of Directors, has elected ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login